论文部分内容阅读
近年来脂质体药物释放系统技术已步入成熟期,目前有几种脂质体药物已处於临床后期考核或已进入市场。许多临床前和临床研究表明,药物(如抗肿瘤药)经脂质体包裹后毒性减弱,但效力仍保持甚至提高。其部分原因是由于改变了药物动力学,使药物在病灶部位(如肿瘤)累积,减少了在敏感组织的分布。正在研制的融合性脂质体系统具有胞内释放药物的能力,预期可提高治疗效果。脂质体设计方面的进展使其在释放新的生物技术产品(如重组蛋白、反义寡核苷酸和克隆基因)方面有了新的应用。
In recent years, liposomal drug delivery system technology has entered its mature stage, there are several liposomal drugs in clinical assessment or have entered the market. Many preclinical and clinical studies have shown that drugs (such as anti-cancer drugs) after liposomes encapsulated decreased toxicity, but the efficacy remains or even increased. This is partly due to changes in pharmacokinetics that allow the drug to accumulate at lesion sites (eg, tumors), reducing the distribution in sensitive tissues. The fusion liposome system under development has the ability to release drugs intracellularly and is expected to improve the therapeutic effect. Advances in liposome design have led to new applications in the release of new biotechnological products such as recombinant proteins, antisense oligonucleotides and cloned genes.